All News

2019

May

Media Release / May 16, 2019

Novartis data at ASCO and EHA demonstrate novel approaches to reimagining medicine in cancer and serious blood disorders

Read More
Vice President and Head of US Hematology at Novartis shares her story for “Novartis Presents: Women in Science.”
Story / May 09, 2019

Women in Science: Sandrine Piret-Gérard

Sandrine Piret-Gérard, Vice President and Head of US Hematology at Novartis, reflects on what’s inspired her career in health care.

Read More

April

Media Release / Apr 30, 2019

Sandoz enters agreement for proposed trastuzumab biosimilar, currently in Phase III development, to treat selected HER2-positive cancer tumors

Read More
Media Release / Apr 24, 2019

Novartis starts 2019 with strong sales and double digit core[1] operating income growth, Mayzent launch and Alcon spin-off; profit guidance upgraded

Read More
Media Release / Apr 03, 2019

Sandoz resubmits biosimilar pegfilgrastim application to US FDA

Read More

March

Retinal ganglion cells
Story / Mar 25, 2019

What goes wrong with the window to the soul in glaucoma?

Speaking with Ganesh Prasanna, Director of Ophthalmology at NIBR.

Read More
A look inside a tumor
Story / Mar 19, 2019

Visualizing immuno-oncology research

Learn how Novartis researchers are working to outsmart tumors.

Read More

January

Media Release / Jan 30, 2019

Novartis delivered strong sales growth with core margin expansion, built leading advanced therapy platforms and focused the company in 2018

Read More
Media Release / Jan 08, 2019

Novartis investigational therapy crizanlizumab (SEG101) receives FDA Breakthrough Therapy designation for the prevention of vaso-occlusive crises in sickle cell disease

Read More
2018

December

Media Release / Dec 21, 2018

Novartis successfully completes acquisition of Endocyte

Read More

Pages

Related Links

Novartis Annual Reporting Suite

Read and download the Annual Review, the Annual Report and Form 20-F, and the Novartis in Society report.

Learn More